NeoImmuneTech

[Not Yet Scheduled]
NeoImmuneTech, Inc. (NIT) is a clinical-stage T cell-focused biopharmaceutical company, dedicated to expanding the horizon of immuno-oncology and enhancing immunity to infectious diseases. Our lead asset NT-I7 (efineptakin alfa) is the only clinical-stage long-acting human IL-7, and is being developed for oncologic and immunologic indications, in which T cell amplification and enhanced functionality may lead to clinical benefit. IL-7 is a fundamental cytokine for naïve and memory T cell development and for sustaining immune response to chronic antigens (as in cancer) or foreign antigens (as in infectious diseases). In clinical trials to date, NT-I7 has exhibited favorable PK/PD and safety profiles, both as a monotherapy and in combination with other anticancer treatments, and has demonstrated encouraging preliminary clinical efficacy in immune cold tumors such as MSS CRC, pancreatic cancer, and high grade glioma. For more information, please visit www.neoimmunetech.com.
Ticker:
950220
Exchange:
Korean stock exchange
Company Type:
Publicly Traded Company
Company Website:
Company HQ State:
Maryland
Company HQ Country:
United States
Year Founded:
Not Provided
Main Therapeutic Focus:
Lead Product in Development:
NT-I7
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided